Zacks Investment Research lowered shares of LHC Group (NASDAQ:LHCG) from a buy rating to a hold rating in a report published on Friday, Zacks.com reports.

According to Zacks, “LHC Group, Inc. is the preferred post-acute care partner for hospitals, physicians and families nationwide. From home health and hospice care to long-term acute care and community-based services, LHC delivers high-quality, cost-effective care that empowers patients to manage their health at home. Hospitals and health systems around the country have partnered with LHC Group to deliver patient-centered care in the home. “

LHCG has been the subject of a number of other research reports. BidaskClub lowered LHC Group from a strong-buy rating to a buy rating in a research note on Thursday, February 28th. UBS Group set a $133.00 price objective on LHC Group and gave the stock a buy rating in a research note on Friday, May 10th. Barclays upped their price objective on LHC Group from $95.00 to $104.00 and gave the stock an equal weight rating in a research note on Thursday, March 21st. Craig Hallum upped their price objective on LHC Group from $93.00 to $114.00 and gave the stock a hold rating in a research note on Friday, March 1st. They noted that the move was a valuation call. Finally, Jefferies Financial Group upped their price objective on LHC Group from $125.00 to $130.00 and gave the stock a buy rating in a research note on Thursday, May 9th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $120.42.

NASDAQ:LHCG opened at $114.91 on Friday. LHC Group has a 52-week low of $80.84 and a 52-week high of $122.20. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.57 and a quick ratio of 1.57. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of 32.37, a P/E/G ratio of 1.95 and a beta of 0.83.

LHC Group (NASDAQ:LHCG) last released its quarterly earnings results on Wednesday, May 8th. The health services provider reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.08. LHC Group had a return on equity of 8.43% and a net margin of 3.83%. The business had revenue of $502.59 million during the quarter, compared to analyst estimates of $511.16 million. Equities research analysts predict that LHC Group will post 4.3 EPS for the current year.

In related news, Director John L. Indest sold 30,515 shares of the stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $113.76, for a total transaction of $3,471,386.40. Following the completion of the transaction, the director now directly owns 22,947 shares of the company’s stock, valued at $2,610,450.72. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronald T. Nixon sold 12,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $117.20, for a total value of $1,406,400.00. Following the transaction, the director now directly owns 29,100 shares of the company’s stock, valued at $3,410,520. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,991 shares of company stock valued at $7,134,055. Corporate insiders own 5.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its stake in LHC Group by 790.0% during the first quarter. Parallel Advisors LLC now owns 267 shares of the health services provider’s stock valued at $30,000 after buying an additional 237 shares during the last quarter. Sageworth Trust Co bought a new position in LHC Group during the first quarter valued at approximately $36,000. Quadrant Capital Group LLC boosted its stake in LHC Group by 1,045.7% during the first quarter. Quadrant Capital Group LLC now owns 527 shares of the health services provider’s stock valued at $57,000 after buying an additional 481 shares during the last quarter. Meeder Asset Management Inc. bought a new position in LHC Group during the first quarter valued at approximately $68,000. Finally, Private Capital Group LLC boosted its stake in LHC Group by 24.4% during the first quarter. Private Capital Group LLC now owns 1,116 shares of the health services provider’s stock valued at $124,000 after buying an additional 219 shares during the last quarter. 91.42% of the stock is owned by institutional investors.

LHC Group Company Profile

LHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations.

See Also: Compound Interest and Why It Matters When Investing

Get a free copy of the Zacks research report on LHC Group (LHCG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.